


 Cite this: *RSC Adv.*, 2021, **11**, 16942

Effect of manganese doping on the hyperthermic profile of ferrite nanoparticles using response surface methodology†

 Ruby Gupta, Ruchi Tomar, Suvankar Chakraverty and Deepika Sharma *

Magnetic hyperthermia-based cancer therapy mediated by magnetic nanomaterials is a promising antitumoral nanotherapy, owing to its power to generate heat under the application of an alternating magnetic field. However, although the ultimate targets of these treatments, the heating potential and its relation with the magnetic behavior of the employed magnetic nanomaterials are rarely studied. Here we provide a bridge between the heating potential and magnetic properties such as anisotropy energy constant and saturation magnetization of the nano-magnets by simultaneous investigation of both hyperthermia and magnetism under a controlled set of variables given by response surface methodology. In the study, we have simultaneously investigated the effect of various synthesis parameters like cation ratio, reaction temperature and time on the magnetic response and heat generation of manganese-doped ferrite nanomaterials synthesized by a simple hydrothermal route. The optimum generation of heat and magnetization is obtained at a cationic ratio of approximately 42 at a temperature of 100 °C for a time period of 4 h. The optimized nanomaterial was then evaluated for *in vitro* magnetic hyperthermia application for cancer therapy against glioblastoma in terms of cell viability, effect on cellular cytoskeleton and morphological alterations. Furthermore, the correlation between the magnetic properties of the synthesized nanomaterial with its hyperthermia output was also established using $K.V.M_s$ variable where K , V and M_s are the anisotropy energy constant, volume, and saturation magnetization of the nanomaterial respectively. It was found that the intensity of heat generation decreases with an increase in $K.V.M_s$ value, beyond 950 J emu g⁻¹.

Received 25th March 2021

Accepted 30th April 2021

DOI: 10.1039/d1ra02376d

rsc.li/rsc-advances

1. Introduction

Magnetic nanoparticles (MNPs) depending on their properties, namely their crystallite size, structure, composition, and physicochemical properties, are being widely investigated for a range of biomedical applications such as magnetic resonance imaging, drug delivery, and hyperthermia.^{1–3} Hyperthermia is a therapeutic technique based upon the generation of localized heat at the tumor site which induces alterations in numerous cellular processes triggering tumor cell death.^{2,3} It can be achieved *via* various modes including radiation, microwave, ultrasound, or magnetic hyperthermia mediated by MNPs.⁴ The application of magnetic hyperthermia therapy for cancer treatment is known as magnetic hyperthermia-mediated cancer therapy (MHCT)^{5,6} and was first attempted by Gilchrist in 1957.⁷ It is based upon exposure of MNPs to an alternating magnetic field (AMF), that raises the temperature from 37 °C to 42–45 °C

locally at the tumor site, inducing death of cancerous cells while the healthy cells remain unaffected.^{8,9}

Owing to its advantages of high tumor penetration with negligible non-specific toxicity, MHCT is being evaluated for various clinical trials for prostate and glioblastoma.¹⁰ However, certain factors limit realization of its complete potential for treatment of inoperable solid tumors like glioblastomas. These include, lack of in-depth understanding of the interaction mechanism of hyperthermia treatment with the cancer cells at the sub-cellular level, incapability of the nanomaterials to generate enough heat inside the cellular compartments to achieve the desired therapeutic effect and presence of biological barriers like the blood–brain barrier, that limits the delivery of the required minimum dose of MNPs at the tumor site.⁴ Besides these limitations, the heat dissipated from the nano-systems is dependent upon various physical factors of the MNPs including its size, morphology and composition along with the physical parameters of the magnetic field applied including the AMF strength and duration of exposure.^{11,12} Thus, with an ultimate goal to maximize the hyperthermia output, MNPs with varied characteristics by altering their synthesis route or reaction parameters, morphology or composition. Table 1 represents summary of some of the nano-systems investigated for *in vitro*

Institute of Nano Science and Technology, Knowledge City, Phase 81, Mohali-140306, Punjab, India. E-mail: deepika@inst.ac.in

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra02376d



Table 1 MNPs design system for *in vitro* MHCT for glioblastoma

MNP system	Size (nm)	AMF parameters			SAR (W g ⁻¹ MNP)	Therapy system	Tumor inhibition achieved (%)	Ref.
		<i>f</i> (kHz)	<i>H</i> (Oe)	ΔT (°C)				
SPIONS (superparamagnetic iron oxide NPs)	15.8	473.5	168	12	113	MHCT	60	13
Co _{0.1} Fe _{2.9} O ₄	7.1	112.6	250	4	13.8	MHCT	40	14
Mn _x Fe _{3-x} O ₄	34	405	168	10.8	600	MHCT-photothermal therapy	70	15
SPIONS	20	753	200	4–5	—	MHCT-chemotherapy	99.8	16
SPIONS	75	780	12.5	6–7	—	MHCT-chemotherapy	49.6	17
Zn-SPIONS	15	522	104	—	743.8	MHCT	50	18
Fe ₃ O ₄	3	405	168	13	80	MHCT	66	19
Fe(salen)	—	280	335	5–6	—	MHCT-chemotherapy	30	20
Fe ₃ O ₄	—	473	150	—	265	MHCT	80–90	21
Zn _{0.9} Fe _{2.1} O ₄	11	700	34.4	4	36	MHCT	20	22

magnetic hyperthermia-mediated glioblastoma therapy, either used alone or in combination with other adjuvant therapies like chemotherapy and photothermal therapy.

As discussed, for unfolding the complete potential of MHCT for solid tumors like glioblastomas, development of new nanomaterials with higher and tunable functionality is very crucial. In this regard, strategy to dope ferrite nanoparticles with other metal atoms has been pursued to achieve high and tunable hyperthermic nanomagnetic systems.^{23–25} For example, a study reports that ferrite nanoparticles simultaneously doped with other metal ions exhibit approximately four-fold higher hyperthermia output as compared to that of conventional iron oxide nanoparticles.²⁶ Also, various studies have reported the hyperthermia output to be highly dependent on magnetic relaxation processes and roughly proportional to the saturation magnetization (M_s) value of the nanomaterials.^{27,28} For nanoparticles, the magnetic properties are very sensitive to the synthesis technique.²⁹ Response surface methodology (RSM) has been significantly used for nanoparticle synthesis for various applications.^{30–34} RSM is an optimizing tool mainly used for evaluating effect of multiple process variables simultaneously as fewer experimental runs are required as compared to investigation of each variable independently. Also, it allows identification and quantification of significant interactions between the variables.

In this paper, we have focused on the effect of manganese (Mn) doping on saturation magnetization and magnetic hyperthermia of ferrite nanoparticles. We have investigated the simultaneous effect of Mn doping by varying synthesis parameters including cation ratio, reaction temperature, and reaction time on magnetic and hyperthermic responses of these samples by RSM technique. The optimum reaction conditions were then deduced to obtain a nanosystem with higher saturation magnetization and hyperthermic efficiency which was further tested for its efficacy in *in vitro* magnetic hyperthermia-based glioblastoma therapy. Further, we have also studied an empirical relation between the magnetic properties of the nanomaterials with their heat generating capabilities that may open a new window in the field of magnetic hyperthermia-based cancer therapy.

2. Experimental section

2.1 Materials

To synthesize the nanoparticles, analytical grade iron chloride hexahydrate (FeCl₃·6H₂O), manganese chloride tetrahydrate (MnCl₂·4H₂O) from Sigma Aldrich were used as initial precursors. Ammonium hydroxide solution (NH₄OH solution; 25%) from Sigma Aldrich was used as the reducing agent.

For cellular studies, normal murine fibroblasts cell line (L929) and human glioma cell line (U87-MG) were purchased from NCCS, Pune, India. The cells were cultured in Dulbecco's Modified Eagles Medium (Hyclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco) and 1% antibiotic-antimycotic solution (Lonza). The cell cultures were grown at 37 °C under 5% CO₂.

2.2 Synthesis of Mn_xFe_{3-x}O₄ nanoparticles

The Mn-doped nanoparticles (Mn_xFe_{3-x}O₄) were synthesized by hydrothermal synthesis route³⁵ with varying cationic ratio (Fe³⁺/Mn²⁺), reaction temperature and time. Different concentrations of FeCl₃·6H₂O and MnCl₂·4H₂O salts (according to stoichiometric ratio of each run) were magnetically dispersed in 11.5 mL deionized water (Table S1†). Then 2.5 mL of NH₄OH as a reducing agent was added into the mixture and air stirred for 10 min. The mixture was then sonicated for 15 min and then added to 23 mL Teflon-lined stainless steel pressure vessel at varying conditions of temperature and time (as per Table S1†). After cooling the reaction mixture to room temperature, the black precipitate obtained was washed with several centrifugation–dispersion cycles with water and ethanol. The final dispersion in water was freeze-dried to obtain the desired Mn_xFe_{3-x}O₄ nanoparticle powder.

2.3 Design of experiments

In this study, the RSM technique was used by DESIGN EXPERT software (V 11.0) to evaluate the effects of different parameters for the synthesis of Mn_xFe_{3-x}O₄ nanoparticles for magnetic hyperthermia-based applications. The design of experiments was done by central composite design (CCD) which is based on



5 defined levels of influential parameters (factors) such as $-\alpha$, -1 , 0 , $+1$, and $+\alpha$. The effect of three independent variables, namely cation ratio of Fe^{3+} and Mn^{2+} ions in the reaction mixture (A), reaction temperature (B) and reaction time (C), were studied on the saturation magnetization (R_1) and total degree rise in temperature on AMF application (R_2). Based on the preliminary work done, the range of independent variables chosen are 0.5–60 (cation ratio), 60–200 °C (reaction temperature) and 2–12 h (reaction time).

For a three-factor system,³⁶ a second-order quadratic equation as given below was fitted to the data by multiple regression procedure:

$$Y = \beta_0 + \beta_1 A + \beta_2 B + \beta_3 C + \beta_{11} A^2 + \beta_{22} B^2 + \beta_{33} C^2 + \beta_{12} AB + \beta_{13} AC + \beta_{23} BC \quad (1)$$

where Y represents the predicted response, β_0 is the intercept; $\beta_1, \beta_2, \beta_3$ are linear coefficients; $\beta_{11}, \beta_{22}, \beta_{33}$ are squared coefficients; $\beta_{12}, \beta_{13}, \beta_{23}$ are interaction coefficients. The whole experimental design consisted of 20 runs carried out in random order. Five replicates of the design were used to allow for the estimation of a pure error sum of squares.

The predicted (using equations obtained for the individual responses) and experimental results for both saturation magnetization (R_1) and total degree rise in temperature (R_2) are presented in Table S1 (ESI file†). The statistical significance of the regression coefficients was evaluated by student's test, and then, the analysis of variance (ANOVA) was performed using only the statistically significant experimental terms. The optimum doping conditions were obtained by response surface and point prediction using Design Expert software.

To verify the optimal conditions and to check the correlation between predicted and measured values, synthesis of Mn-doped ferrite nanoparticles was carried out using the optimal reaction parameters given by the software *i.e.* cationic ratio of approximately 42 at 100 °C for 4 h. Under these conditions, the synthesized nanoparticles were predicted to have saturation magnetization of 75 emu g^{-1} and 6 °C rise in temperature on AMF application. The optimal nanoparticles were also coated *in situ* with polyethylene glycol (PEG-2000) under identical conditions. To do so, 0.13 M PEG-2000 was initially magnetically stirred into 11.5 mL water for 1 h followed by the same protocol as described earlier for synthesis of Mn-doped nanomaterials.

2.4 Characterization of nanoparticles

2.4.1 Physical characterization of the MNPs. The crystallite structure and size of the synthesized nanoparticles were determined by X-ray diffraction (XRD) using Bruker D8 Advanced system (Billerica, Massachusetts, USA) equipped with Cu K_α radiation source from 20 to 70° (2θ) with an increment of 0.02° min^{-1} . Moreover, the hydrodynamic size and the surface charge of the nanoparticles were calculated based on dynamic light scattering (DLS) technique using Malvern Zetasizer Nano-ZS (Malvern, Worcestershire, USA). The particle size and the morphology of the nanoparticles were investigated by transmission electron microscope (TEM) operating at an accelerating voltage of 200 kV using JEOL JEM 2100 TEM system (Akishima, Tokyo, Japan).

Next, to determine Fe and Mn content in the nanoparticles, ICP-MS was done. Briefly, 50 mg of the MNPs were digested with ICP grade HNO_3 and heated at 80 °C until a clear solution was formed. The volume of the sample was made upto 50 mL with deionized water. The samples were then analyzed with the help of Agilent 7700 series ICP-MS system (Santa Clara, California, USA). X-ray photoelectron spectroscopy (XPS) was further done to confirm the elemental composition of the optimally synthesized Mn-doped Ferrite MNPs using Nexsa base spectrophotometer (ThermoFisher Scientific, Waltham, Massachusetts, USA). The PEG-2000 coating onto the surface layer of optimal MNPs was further confirmed by Agilent Fourier transform infrared (FTIR) 600 series spectrometer (Santa Clara, California, USA).

2.4.2 Magnetic properties of the MNPs. The magnetic measurements were performed in vibrating sample magnetometer (VSM) probe installed on Quantum Design Dynacool Physical Property Measurement System (PPMS) (California, USA). For all the samples, the magnetic measurements were done as a function of magnetic field at 300 K and as a function of temperature in the presence of an applied field of 100 Oe.

The parametric dependence of magnetic parameters of a nanomaterial, namely anisotropy energy constant, saturation magnetization on its thermal profile when exposed to an alternating magnetic field was further studied. To calculate the anisotropy energy constant for all the samples, time dependent magnetization was measured at room temperature. In the process, relaxation of magnetization was measured as a function of time after the externally applied magnetic field was switched off. The relaxation time constant was calculated using the following equation:

$$M(t) = M_0 e^{-t/\tau} \quad (2)$$

where M_0 is the saturation magnetization on application of 1000 Oe field, $M(t)$ is the magnetization as a function of time after turning off the magnetic field, τ is the magnetic relaxation time constant of the nanoparticles in seconds.

Then the anisotropy energy constant was calculated by using the following equation:

$$\tau = \tau_0 e^{KV/TK_B} \quad (3)$$

where τ_0 is a constant of value 10^{-9} s, V is the volume of the nanoparticle (m^3), T is the temperature (300 K) and K_B is the Boltzmann constant with value $1.38 \times 10^{-23} \text{ m}^2 \text{ kg s}^{-2} \text{ K}^{-1}$.

2.5 Magnetic hyperthermia measurements

The calorimetric magnetic hyperthermia efficiency of the synthesized magnetic $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$ nanoparticles was calculated using the DM2 equipped DM100 nanomagnetic heating system by nB nanoscale Biomagnetics (Zaragoza, Spain). The aqueous nanoparticle dispersions were subjected to an AC magnetic field (f) at 405 kHz with a field amplitude (H) of 168 Oe for 1200 s to determine the increase in temperature. A fluoro-optic thermometer fiber probe was used to probe the temperature every 0.2 s after switching on the magnetic field.



The hyperthermia output was investigated in terms of the specific absorption rate (SAR), which is defined as the power dissipation per unit mass of nanoparticle (W g^{-1}), calculated by using the following equation:

$$\text{SAR } (\text{W g}^{-1}) = \frac{C}{m} \frac{dT}{dt} \quad (4)$$

where C represents the specific heat of the solution that is assumed to be same as that of pure water ($C_w = 4.185 \text{ J g}^{-1} \text{ K}^{-1}$), dT/dt is the slope of the temperature-vs.-time graph in the initial seconds and m is the weight of the nanoparticles in the solution.

However, due to the existence of discrepancies in SAR value owing to its strong dependence on magnetic field parameters, the hyperthermia output was further evaluated in terms of intrinsic loss power (ILP) given as:

$$\text{ILP } \left(\frac{\text{nHm}^2}{\text{kg}} \right) = \frac{\text{SAR}}{H^2 f} \quad (5)$$

2.6 Cellular studies

The biocompatibility of the optimal MNPs ($0\text{--}1000 \mu\text{g mL}^{-1}$), both bare and PEG-coated, were determined on L929 cell lines for a period of 24 h using MTT assay. The cytotoxic effect of the hyperthermic treatment in presence of optimal PEG-MNPs was then evaluated on U87-MG cell line by MTT assay. The treatment controls were established as follows: (a) untreated cells; (b) cells treated with heat alone for 20 min; (c) cells treated with MNPs alone for 20 min; (d) cells analyzed immediately after heat treatment for 20 min in the presence of MNPs, (e) cells analyzed post-24 h of heat treatment for 20 min in the presence of MNPs.

The effect of heat treatment on cytoskeleton of glioma cells was also analyzed by confocal microscopy. For the experiment, PEG-MNPs was conjugated to Rhodamine 6G (R6G; Invitrogen) by incubating $500 \mu\text{g mL}^{-1}$ MNPs with $50 \mu\text{g mL}^{-1}$ R6G at RT for 12 h. After heat treatment in presence of R6G-PEG-MNPs, U87-MG cells were fixed with 4% paraformaldehyde for 5 min at RT. The cells were then stained with Hoechst-33342 ($5 \mu\text{g mL}^{-1}$) for 5 min followed by cytoskeletal staining with Fluorescein Phalloidin (Invitrogen) for 20 min. The cells were rinsed with PBS and mounted on a glass slide to visualize under Zeiss LSM880 confocal microscope (Carl Zeiss, Thornwood, New York).

The changes in cellular morphology were further determined by using a JEOL JSM-IT300 scanning electron microscope (Akishima, Tokyo, Japan).¹⁵ For the analysis, glioma cells were grown to confluency on coverslips in 35 mm tissue culture Petri-plates. Post-heat treatment for 20 min, cells were fixed with 2.5% glutaraldehyde containing 0.1 M phosphate buffer for 60 min at 4°C . Following incubation, samples were serially dehydrated using graded ethanolic solutions (10%, 25%, 50%, 75% and 100%) for 20 min each. After air-drying, samples were sputter coated with gold-palladium before SEM analysis.

3. Results and discussion

3.1 Physical properties of the MNPs

The crystallite structure of the Mn-doped ferrite nanoparticles was determined by X-ray diffraction (Fig. 1(A)). No traces of other iron oxide phases were found which suggest the formation of single phase $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$ nanoparticles. The relative intensity and position of all peaks match well with the standard magnetite (Fe_3O_4) crystal.³⁷ Further characterizations including the estimation of crystallite size, lattice constant, hydrodynamic size, surface charge and dopant value (x) of all the nanomaterials generated in the study were done to determine the nature and composition of all the nanomaterials synthesized in each reaction (ESI file; Table S2†). The lattice parameter obtained for all the synthesized nanoparticles correlates well with the reported values for that of Mn-ferrite nanomaterials.^{15,37} The variation in lattice constant observed in comparison to the reported value for Fe_3O_4 MNPs (0.836 nm),³⁸ further indicates successful doping of Mn ions into ferrite structure.¹⁵

Fig. 1(B) shows the MH curve at room temperature for all the synthesized magnetic nanoparticles suggesting that the saturation magnetization of the particles was found to vary between $40\text{--}83 \text{ emu g}^{-1}$ with change in the selected factors. The graph shows that the run order 12 corresponding to maximum doping shows minimum M_s of 41 emu g^{-1} and the one corresponding to minimum doping (run order 19) shows a higher M_s of 75 emu g^{-1} . While the maximum value of M_s (83 emu g^{-1}) was observed for medium level doped NPs (run order 9 and 10). This is consistent with the various studies, which report that magnetic properties of the nanoparticles are




Fig. 1 (A) X-ray diffraction pattern of Mn-ferrite nanoparticles synthesized; (B) magnetization as a function of applied magnetic field of the MNPs synthesized; (C) total degree rise in temperature by MNPs on application of AMF of strength 405 kHz and 168 Oe for 20 min. The numbers represent the run order.



affected by the doping percentage.^{39,40} Table S3† lists the magnetic properties of all the synthesized nanosystems.

The magnetization as a function of temperature for the nanoparticles exhibiting maximum magnetization (run order 9) and maximum degree rise in temperature (run order 1) are shown in ESI Fig. S2(A) and (B),† respectively.

The hyperthermia profile of all the $Mn_xFe_{3-x}O_4$ nanoparticles was determined on application of AMF (405 kHz and 168 Oe) for 20 min (Fig. 1(C)). The results indicated that the maximum temperature rise (5.7 °C) was achieved for nanoparticles synthesized at the lower cationic ratio at low temperature (run order 1) while the minimum temperature rise (0.7 °C) was observed for nanoparticles synthesized using higher cationic ratio at a higher temperature (run order 4). The SAR and ILP values obtained for all the MNPs are presented in Table S3 (ESI file†). As observed in the table, the SAR values obtained for the synthesized nano-systems are lower than that obtained for some of the reported systems^{41–43} but are also in accordance with other reported systems used for applications in nanotheranostic-based cancer therapy.^{44–47} A micromode ferrofluid (size ~7 nm) is one such example of magnetic nano-systems employed for commercial purposes despite of lower ILP of 0.15–0.37 nHm² kg⁻¹.⁴⁸ Thus, indicating that the MNPs generated in the study can be used for hyperthermia therapy.

Some of the as-synthesized $Mn_xFe_{3-x}O_4$ nanoparticles corresponding to run orders 7, 2, 6 and 1, were observed under TEM to determine the crystallite size of the nanomaterials (Fig. 2). The crystallite sizes obtained for these nanomaterials were determined to be 28.3 ± 1.7 nm, 25.1 ± 0.9 nm, 16.7 ± 1.1 nm and 17.5 ± 2 nm, respectively. The results indicate the generation of nearly spherical nanoparticles with size differences due to synthesis under different reaction conditions. With lower Mn doping, the crystallite size of the nanoparticles were observed to be greater (~25 nm) than that obtained for higher Mn doped nanoparticles (~17 nm). In accordance with this finding, various other studies have also reported changes in crystallite size of the nanoparticles on introducing dopants in the lattice structure of the material.^{15,37}

A brief description of the electronic properties of Mn-doped Fe_3O_4 nanoparticles studied theoretically is given below. Sharifi *et al.* performed density functional theory (DFT) simulations to check changes in the geometrical and electronic properties of $MnFe_2O_4$.⁴⁹ For this study, they considered both normal and inverse spinel structures and all of them were ferrimagnetic. To confirm, they further computed the XRD patterns optimized by DFT calculations and concluded that its XRD pattern is a combination of normal and inverse spinel structures. Electronic band structures and atom-projected density of states of




Fig. 2 Representative TEM images of the Mn-ferrite nanoparticles synthesized corresponding to (A) run order 7; (B) run order 2; (C) run order 6; and (D) run order 1 (scale bar = 100 nm). The size distribution histograms are represented as insects.



Table 2 Lattice constants, spin-up gap, and spin-down gap calculated by DFT

	a (Å)	c (Å)	Spin up gap (eV)	Spin down gap (eV)
Normal spinel	6.14	8.68	1.4 (indirect)	4.5 (direct)
Inverse spinel	5.96	8.71	0	0

the considered structures suggest that the normal spinel MnFe_2O_4 is an insulator whereas the inverse spinel MnFe_2O_4 is predicted to be conducting in nature which has not been observed experimentally. The lattice constants, spin-up gap, and spin-down gap of the considered structures calculated by DFT are listed in Table 2 given below. According to the atom-projected DOS of normal and inverse MnFe_2O_4 spinel structures, they suggested that MnFe_2O_4 is a combination of 20% inverse and 80% normal spinel structures. It was also seen that the density of states near the Fermi level of MnFe_2O_4 is higher. Brabers *et al.* have shown that two types of cation migration take place in $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$.⁵⁰ At 200 °C, the cation exchange between the octahedral and tetrahedral sublattices occurs in the entire system and the octahedral Mn^{3+} clustering occurs only in that part of the system rich in manganese. As observed, $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$ shows two crystal structures at room temperature *i.e.*, cubic spinel structure when $x < 1.9$ and tetragonally deformed spinel structure when $x > 1.9$.

As for the magnetic properties of $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$, Miao *et al.* have shown that its magnetization increases first up to some value of x (≤ 0.37) and above this value of x , it starts decreasing.⁵¹ As known, MnFe_2O_4 has a mixed spinel structure with the Mn ions predominantly occupying tetrahedral sites. Mn^{2+} has five unpaired electrons, which is the same number as in Fe^{3+} , and one more than in Fe^{2+} . For $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$ with small x values, the Mn^{2+} dopant can replace Fe^{2+} to give a magnetic moment of $(4 + x) \mu_B$ per formula unit, resulting in an enhanced magnetic moment in comparison with $[\text{Fe}^{3+}]_T[\text{Fe}^{2+}\text{Fe}^{3+}]_O\text{H}_4$. However, as the doping level further increases, the magnetization gradually decreases ($x = 1.57$) due to the weakening of the T_d - O_h interaction when Fe^{3+} is replaced by Mn^{2+} in the T_d site.⁵²⁻⁵⁴

3.2 Central composite design (CCD) and response surface analysis

The fitted model equation to determine the saturation magnetization (R_1) of the nanomaterials can be defined as follows:

$$R_1 = 74.22 + 7.20A + 2.53B - 1.08C - 0.6738AB + 2.32AC - 0.0113BC - 4.17A^2 + 2.67B^2 - 2.13C^2 \quad (6)$$

where R_1 is the saturation magnetization of the MNPs and A , B and C are the respective factors namely cation ratio, temperature and time of the reaction, respectively.

For testing the fit of the model, the regression equation and determination of coefficient (R^2) were evaluated. The model




Fig. 3 3D plot representing (A) saturation magnetization and (B) temperature rise as a function of cation ratio and reaction temperature. The 3D response surface plots obtained by RSM for (C) saturation magnetization and (D) temperature rise.



presented a high determination of coefficient value ($R^2 = 0.7831$) which suggests that 78.31% of the variables; cation ratio, reaction temperature and time were supported by the response.^{55,56} The corresponding ANOVA analysis of the fitted model for saturation magnetization (R_1) is presented in Table S4.† The ANOVA of quadratic regression model as presented from the Fisher's F -value of 4.01 with P -value corresponding to 0.0205 (<0.05) demonstrated that the model was significant. As seen in Table S4,† the linear effect of cationic ration (A) and its squared term had the maximum effect on the response with the cation ratio variable (A) being the most significant factor in determining the outcome of the model ($P < 0.005$).

The fitted model equation for the total degree rise in temperature, represented by R_2 , is as follows:

$$R_2 = 3.73 - 0.1857A - 0.8730B - 0.0972C - 0.4250AB - 0.1000AC + 1.15BC - 0.2973A^2 - 0.6686B^2 + 0.1623C^2 \quad (7)$$

where R_2 is the total degree rise in temperature achieved on AMF application ($f = 405$ kHz and 168 Oe).

The model presented a high determination of coefficient ($R^2 = 0.8800$) suggesting that 88% of the variables were also supported by the response. The corresponding ANOVA analysis of the fitted model for total degree rise in temperature (R_2) is presented in Table S5.† The Fisher's F -value of 8.15 with P -value corresponding to 0.0015 (<0.005) of the model demonstrated that the model was significant. As seen in Table S5,† the linear effect of reaction temperature (B), the interaction of reaction temperature (B) and time (C), and the squared effect of reaction temperature (B^2) forms the most significant factors in determining the outcome of the model ($P < 0.005$) with the first two terms being highly significant model terms ($P < 0.0005$).

The 3D response surface plots represent graphical description of the regression equation to determine the optimum values of the variables taken within the ranges considered, such that the response is maximized.⁵⁷ The respective plots for both responses, saturation magnetization and hyperthermic rise are presented in Fig. 3. Fig. 3(A and B) represent the saturation magnetization and the temperature rise (hyperthermia output), respectively as a function of both cation ratio and reaction temperature for all the 20 experimental runs. Each contour curve at the base of the 3D response curves, constitutes of an

infinite number of combinations of two test variables with the third variable maintained at its respective zero level. Elliptical shape of the contours represents perfect interaction between the independent variables.⁵⁸⁻⁶⁰ Thus, the elliptical nature of the contours suggests that the variables chosen in the study directly influence the outcome of the responses.

Further, as seen in Fig. 3(C and D), the response surface graphs obtained for both responses were elliptical in the entire region. The maximum response values are achieved at the point of intersection of major and minor axes of the ellipse. The cation ratio acts as one of the key variables affecting the magnetic property of the $\text{Mn}_x\text{Fe}_{3-x}\text{O}_4$ nanoparticles.

The set of experiments in the RSM resulted in an optimum set of independent variables in order to obtain the higher levels of saturated magnetization with maximum total degree rise in temperature on AMF application. The regression coefficient (R_2) value of 0.783 (in case of R_1 ; saturation magnetization) and 0.880 (for R_2 ; hyperthermia output) showed a good fitting of the model with the experimental data obtained, and the model predicted accurately the maximum point of saturation magnetization of the optimal nanoparticle synthesized.

3.3 Effect of magnetic properties on hyperthermia profile

The parametric dependence of magnetic parameters of a nano-material, namely anisotropy energy constant, saturation magnetization and the thermal profile of the nanoparticles when exposed to an alternating magnetic field was further studied.

Fig. 4(A and B) show the total degree rise in temperature as a function of anisotropy energy constant and saturation magnetization, suggesting no correlation between them.

The total degree rise in temperature was then plotted as a function of the $K.V.M_s$ value which suggests that on increasing $K.V.M_s$, initially ΔT decreases slowly until it reaches approximately 950 J emu g^{-1} . Beyond this, ΔT decreases rapidly with further increase in $K.V.M_s$ value (Fig. 4(C)).

The magnetic measurements combined with magnetic hyperthermia suggest that a nanoparticle with $K.V.M_s$ value lying in the region shaded blue ($K.V.M_s < 950 \text{ J emu g}^{-1}$) in Fig. 4(C) will exhibit superior heat generating capabilities for successful use in biomedical applications. Hence, the $K.V.M_s$




Fig. 4 Effect of (A) anisotropy energy constant (K), (B) saturated magnetization (M_s) and (C) $KV \times M_s$ on total degree rise in temperature ΔT on application of AMF of strength 405 kHz and 168 Oe for 20 min.



value for the magnetic nanoparticles can be considered as a good measure of magnetic parameter regarding hyperthermic effect.

3.4 Verification of optimum conditions

To confirm aforementioned results, the synthesis of Mn-doped ferrite nanoparticles was conducted under the optimum conditions calculated by response surface analysis to achieve optimal amounts of both saturation magnetization (R_1) and total degree rise in temperature (R_2). According to the software, synthesizing MNP using cation ratio ($\text{Fe}^{3+}/\text{Mn}^{2+}$) of 42 at 100 °C for 4 h as the reaction temperature and time, respectively would yield $\text{Mn}_{0.07}\text{Fe}_{2.93}\text{O}_4$ nanoparticles with saturation magnetization of 75 emu g^{-1} and $6 \text{ }^\circ\text{C}$ degree rise in temperature on AMF application. Based on these results, the nanoparticles with higher magnetic properties and heat generation capabilities were generated at the higher $\text{Fe}^{3+}/\text{Mn}^{2+}$ ratio, lower temperature and shorter duration of time.

The crystallite structure of the optimal Mn-doped ferrite samples synthesized was confirmed by X-ray diffraction (Fig. 5(A)). The average particle size of the synthesized nanoparticle was found to be $19.2 \pm 2.3 \text{ nm}$ with spherical morphology as obtained by TEM image analysis using Digital Micrograph software (Fig. 5(B)). The size distribution profile is shown in ESI Fig. S1.† Fig. 5(C) represents the DC hysteresis loops of the optimal sample synthesized at 300 K. As shown in the graph, negligible hysteresis is observed which indicates the superparamagnetic behavior of the nano-systems. The M_s

obtained for the sample is 73 emu g^{-1} which is very similar to that predicted by RSM (75 emu g^{-1}). The magnetic properties of the particle as a function of temperature when 100 Oe field is applied is shown in ESI Fig. S2(C).†

Fig. 5(D) shows the hyperthermia profile of the nanoparticles when exposed to an AMF of strength 405 kHz and 168 Oe for 20 min. Though RSM predicted rise in temperature on AMF application to be about $5.5 \text{ }^\circ\text{C}$, we observed a total degree rise of $8.4 \text{ }^\circ\text{C}$ in temperature on AMF application Fig. 5(D).

The results demonstrate that the correlation between predicted and measured value of these experiments verified the validity of the response model and the existence of an optimum point.

Overall, in this study, the RSM technique proved to be a powerful tool for optimizing the magnetic behavior by manganese doping. In the present work, all variables were positively significant factors, the proposed model equations and the optimum condition results illustrate the interaction between the factors in case of R_1 (saturation magnetization).

The investigation of the elemental composition of the optimally synthesized Mn-ferrite MNPs was further done using XPS in the 0–1300 eV region. The survey spectrum (Fig. 6(A)) indicates the presence of all Fe, Mn and O in the nanomaterial indicating successful doping of Mn ions in the ferrite structure.¹⁵ The high-resolution XPS spectra of Fe 2p, Mn 2p and O 1s respectively of the MNPs, is represented in Fig. 6(B–D). The presence of doublet characteristic peaks of Fe^{3+} and Fe^{2+} in the Fe 2p spectra (Fig. 6(B)) confirms the formation of Fe_3O_4 .⁶¹




Fig. 5 Synthesis and characterization of the optimal Mn-doped ferrite nanoparticle. (A) X-ray diffraction pattern, (B) TEM image, (C) hysteresis loop at 300 K, (D) the temperature change on application of AMF of strength 405 kHz and 168 Oe for 20 min.






Fig. 6 (A) Survey scan of optimal Mn-ferrite MNPs, XPS spectra of (B) Fe 2p, (C) Mn 2p and (D) O 1s of the MNPs.

Further, deconvolution of the Mn 2p electron peaks presented three valence states of Mn atoms corresponding to Mn^{2+} , Mn^{3+} , and Mn^{4+} in the ferrite structure (Fig. 6(C)). The presence of these Mn valence states validates interaction of Mn ions with oxygen atoms.⁶² The deconvolution of O 1s photoelectron spectrum into two O^{2-} chemical state characteristic peaks corresponding to O and O^{1-} further confirms formation of Fe_3O_4 based nanomaterial (Fig. 6(D)).⁶³ The structure coordinates of the synthesized nanosystem is presented in Table S6.†

After confirmation of generation of optimal Mn-doped Fe_3O_4 nanoparticles, the MNPs was further coated with PEG to be applied for magnetic hyperthermia-mediated cancer therapy (MHCT) against glioma cells. Surface functionalization of the MNPs with PEG was confirmed by FTIR analysis (ESI Fig. S3†). Before starting with the *in vitro* experiments, the PEG-coated Mn-doped Fe_3O_4 nanoparticles (PEG-MNPs) were investigated for their capability to generate heat as a function of variable AMF frequency and field strength (Fig. 7).

Fig. 7(A) represents rise in temperature (ΔT) achieved when PEG-MNPs were subjected to AMF of field strength 168 Oe and frequency ranging from 405–637.6 kHz. While Fig. 7(B) represents rise in temperature achieved on exposure of PEG-MNPs to variable field strength (168–264 Oe) with fixed AMF frequency of 405 kHz. The frequency (f) and field (H) were varied such that the product Hf remains the same in both graphs (Fig. 7(A and B)). As seen in the graphs, hyperthermia output in terms of ΔT increased with increasing frequency and field, respectively. Fig. 7(C and 6D) further represent the SAR value obtained when the MNPs were subjected to the variable

frequency and field, respectively. The inset values corresponds to the Hf product value obtained respectively by varying the AMF frequency and field accordingly. As the PEG-MNPs demonstrate the capability to achieve the desired hyperthermia window ($\Delta T = 5\text{--}8\text{ }^\circ\text{C}$) even at the lowest AMF parameters, *i.e.* $H = 168\text{ Oe}$ and $f = 405\text{ kHz}$, the synthesized MNPs were further evaluated for their potential to be employed as theranostic agents for *in vitro* magnetic hyperthermia applications against solid tumors like glioma.

3.5 *In vitro* magnetic hyperthermia

Even though the understanding of how MHCT interacts with cancer cells causing their cell death is limited, it is known to be dependent upon the temperature achieved and the duration of AMF exposure.⁶⁴ Localized heat generation has been shown to be responsible for any alterations in cellular processes that causes magneto-thermal stress in cells inducing tumor cell death. One of the possible modes of action of hyperthermia on reduced cell viability includes induction of protein denaturation as stability of the proteins is greatly influenced by thermal changes.⁶⁵ Thus, this affects the processing of various downstream signaling pathways^{66,67} like progression through the cell cycle, DNA repair mechanisms, activation of immune cells and effect on protein synthesis.^{68–70} Furthermore, the magneto-thermal stress can also be conducive to an adverse impact on the cellular cytoskeleton structure, membrane integrity, intracellular transport, mitochondrial membrane potential, and RNA processing.^{15,19,71} In addition, elevated temperatures have also been shown to cause temporary disruption of the biological barriers including blood–brain barrier, leading to increased






Fig. 7 Calorimetric hyperthermia measurements of PEG-MNPs as a function of (A) frequency of AMF, (B) AMF field strength. SAR as a function of (C) AMF frequency and (D) AMF field strength. Blue shaded region in A and B represents the hyperthermia window.

permeability of therapeutic payloads into the brain tissues for treatment of brain disorders.^{72,73} Besides these interactive mechanisms, the cells surviving hyperthermia treatment activate their defense mechanism by increasing expression levels of certain chaperone proteins known as heat shock proteins, which are majorly responsible for rendering tumor cells thermo-resistance.^{74,75}

Despite the multitude of MHCT interaction mechanisms with tumour cells, its clinical translation is limited, mainly due to reduced heat generating capability of nanosystems inside cellular environment and the induction of thermotolerance which renders MHCT less effective. Hence, optimization of nanoparticle design is required to develop highly efficient heat generating systems to achieve the desired therapeutic outcomes.

For this, the nanoparticles corresponding to the optimized synthesis parameters for maximum hyperthermia output and high magnetization, were then evaluated for their potential to be used as hyperthermia agents for glioblastomas.

The optimal Mn-doped ferrite nanomaterial coated with PEG-2000 (PEG-MNPs) was observed to be non-toxic till concentration of $750 \mu\text{g mL}^{-1}$ while the bare MNPs were observed to be biocompatible till the concentration of $500 \mu\text{g mL}^{-1}$ when tested on murine L929 cells (Fig. 8(A)) suggesting the surface functionalization of the MNPs with PEG to be attributed for the enhanced biocompatibility observed. All the *in vitro* cytotoxicity assays were performed using $500 \mu\text{g mL}^{-1}$ concentration of PEG-MNPs.

After determining the biocompatibility of the material, *in vitro* cytotoxic assay was performed (Fig. 8(B)). The results

demonstrated that exposure of cells to heat in the presence of the synthesized nanomaterial ($500 \mu\text{g mL}^{-1}$) resulted in decrease in percentage cell viability to $\sim 60\%$ as compared to cell viability observed nearly 75% in presence of MNPs alone. Moreover, re-culturing the cells for 24 h after heat exposure in presence of MNPs further resulted in decrease in cell viability to $\sim 30\%$. This demonstrates the long-term effect of heat treatment on glioma cells using the synthesized nanomaterial. The control cells, both untreated and exposed to heat alone, maintained their viabilities $\sim 100\%$, suggesting that heat alone has no cytotoxic effect on cancer cells. As described earlier, this reduced cell viability of glioma cells on hyperthermia treatment could be attributed to the effect of heat generated on various cellular processes like protein denaturation, enhanced oxidative stress and DNA damage.^{70,71}

Besides the above suggested causes of glioma cell death, the effect of hyperthermia treatment on cellular cytoskeleton (Fig. 8(C)) and cellular morphology (Fig. 8(D)) was further investigated by confocal microscopy and SEM analysis, respectively and compared to that of the untreated control glioma cells. As seen in the figure, exposure of glioma cells to heat stress caused evident cellular damage that ultimately resulted in cancer cell death. Our results suggests that MHCT in the presence of the optimally synthesized nano-magnetic system generated enough heat to cause plasma membrane disruption that altered various cellular processes, inducing magnetothermal stress in cells as exhibited by the distorted cytoskeleton also, causing remarkable glioma cell death. Thus, our study indicates the potential of the synthesized manganese






Fig. 8 Cellular studies. (A) Biocompatibility assay on L929; (B) *in vitro* magnetic hyperthermia on human glioma U87-MG cell line, where 1-control cells, 2-cells treated with heat alone; 3-cells treated with MNP alone; 4-cells analyzed immediately after heat treatment for 20 min in the presence of MNPs, 5-cells analyzed post-24 h of heat treatment for 20 min in the presence of PEG-MNPs; (C) confocal microscopy to detect cytoskeletal damage and (D) scanning electron microscopy of untreated control and after 24 h of heat treatment to U87-MG cells (scale bar = 10 µm).

ferrite nanosystem to be employed as hyperthermic agent for treatment of solid tumors.

4. Conclusion

Realizing the “good-parameter” that controls magnetic hyperthermia efficiently and systematically is a long-standing issue. We have performed a systematic case study on ferrite magnetic nanoparticles using response surface methodology resulted in an optimum set of independent variables to obtain the desired levels of magnetic hyperthermia output. Our result indicated that the value of saturation magnetization observed for the optimal sample was 73 emu g^{-1} and the temperature rise achieved on AMF application was $8.4 \text{ }^\circ\text{C}$ by optimized condition given by RSM. Our experiments on this test material revealed that a product of magnetic anisotropy energy, volume of the nanoparticles and saturation magnetization could be regarded as a “good-parameter” rather than M_s alone to predict and design efficient and desirable magnetic hyperthermic materials. Our method is not restricted to any particular system and can be extended to any material.

Conflicts of interest

The authors have no conflict to declare.

Acknowledgements

This work was supported by the DST-SERB [grant number ECR/2017/000049]; DST Nanomission [grant number SR/NM/NS-1007/2015(G)] (for PPMS magnetometer facility at Institute of Nano Science and Technology (INST), Mohali).

Notes and references

- 1 K. Hayashi, Y. Sato, W. Sakamoto and T. Yogo, *ACS Biomater. Sci. Eng.*, 2017, **3**, 95–105.
- 2 S. Liébana-Viñas, K. Simeonidis, U. Wiedwald, Z.-A. Li, Z. Ma, E. Myrovali, A. Makridis, D. Sakellari, G. Vourlias, M. Spasova, M. Farlea and M. Angelakeris, *RSC Adv.*, 2016, **6**, 72918.
- 3 S. Laurent, S. Dutz, U. O. Häfeli and M. Mahmoudi, *Adv. Colloid Interface Sci.*, 2011, **166**, 8–23.
- 4 R. Gupta and D. Sharma, *ACS Chem. Neurosci.*, 2019, **10**, 1157–1172.
- 5 A. Jordan, R. Scholz, P. Wust, H. Fähling and R. Felix, *J. Magn. Magn. Mater.*, 1999, **201**, 413–419.
- 6 R. Hergt, S. Dutz, R. Müller and M. Zeisberger, *J. Phys.: Condens. Matter*, 2006, **18**, S2919–S2934.
- 7 R. K. Gilchrist, R. Medal, W. D. Shorey, R. C. Hanselman, J. C. Parrott and C. B. Taylor, *Ann. Surg.*, 1957, **146**, 596–606.



- 8 H. Kenneth, M. D. Luk, R. M. Hulse and T. L. Phillips, *West. J. Med.*, 1980, **132**, 179–185.
- 9 J. R. Oleson, S. K. Calderwood, C. T. Coughlin, M. W. Dewhirst, L. E. Gerweck, F. A. Gibbs and D. S. Kapp, *Am. J. Clin. Oncol.*, 1988, **11**, 368–380.
- 10 B. Thiesen and A. Jordan, *Int. J. Hyperthermia*, 2008, **24**, 467–474.
- 11 N. R. Datta, S. Krishnan, D. E. Speiser, E. Neufeld, N. Kuster, S. Bodis and H. Hofmann, *Cancer Treat. Rev.*, 2016, **50**, 217–227.
- 12 X. Liu, Y. Zhang, Y. Wang, W. Zhu, G. Li, X. Ma, Y. Zhang, S. Chen, S. Tiwari, K. Shi, S. Zhang, H. M. Fan, Y. X. Zhao and X. J. Liang, *Theranostics*, 2020, **10**, 3793–3815.
- 13 L. Dallet, D. Stanicki, P. Voisin, S. Miraux and E. J. Ribot, *Sci. Rep.*, 2021, **11**, 3286.
- 14 A. G. Leonel, A. A. P. Mansur, S. M. Carvalho, L. E. F. Outon, J. D. Ardisson, K. Krambrock and H. S. Mansur, *Nanoscale Adv.*, 2021, **3**, 1029–1046.
- 15 R. Gupta and D. Sharma, *ACS Appl. Nano Mater.*, 2020, **3**, 2026–2037.
- 16 C. Pucci, D. De Pasquale, A. Marino, C. Martinelli, S. Lauciello and G. Ciofani, *ACS Appl. Mater. Interfaces*, 2020, **12**, 29037–29055.
- 17 A. Bazzazzadeh, B. F. Dizaji, N. Kianinejad, A. Nouri and M. Irani, *Int. J. Pharm.*, 2020, **587**, 119674.
- 18 P. Das, L. Salvioni, M. Malatesta, F. Vurro, S. Mannucci, M. Gerosa, M. Antonietta Rizzuto, C. Tullio, A. Degrassi, M. Colombo, A. M. Ferretti, A. Ponti, L. Calderan and D. Prospero, *J. Colloid Interface Sci.*, 2020, **579**, 186–194.
- 19 R. Gupta and D. Sharma, *Int. J. Hyperthermia*, 2019, **36**, 302–312.
- 20 M. Ohtake, M. Umemura, I. Sato, T. Akimoto, K. Oda, A. Nagasako, J. H. Kim, T. Fujita, U. Yokoyama, T. Nakayama, Y. Hoshino, M. Ishiba, S. Tokura, M. Hara, T. Muramoto, S. Yamada, T. Masuda, I. Aoki, Y. Takemura, H. Murata, H. Eguchi, N. Kawahara and Y. Ishikawa, *Sci. Rep.*, 2017, **7**, 42783.
- 21 G. Hemery, C. Genevois, F. Couillaud, S. Lacomme, E. Gontier, E. Ibarboure, S. Lecommandoux, E. Garanger and O. Sandre, *Mol. Syst. Des. Eng.*, 2017, **2**, 629–639.
- 22 A. Hanini, L. Lartigue, J. Gavard, K. Kacem, C. Wilhelm, F. Gazeau, F. Chau and S. Ammar, *J. Magn. Magn. Mater.*, 2016, **416**, 315–320.
- 23 J. W. Strohbehn and E. B. Duple, *IEEE Trans. Biomed. Eng.*, 1984, **31**, 779–787.
- 24 Y. W. Jun, J. H. Lee and J. Cheon, *Angew. Chem., Int. Ed.*, 2008, **47**, 5122–5135.
- 25 Y. Qu, J. Li, J. Ren, J. Leng, C. Lin and D. Shi, *ACS Appl. Mater. Interfaces*, 2014, **6**, 16867–16879.
- 26 M. Zhang, Y. Cao, L. Wang, Y. Ma, X. Tu and Z. Zhang, *ACS Appl. Mater. Interfaces*, 2015, **7**, 4650–4658.
- 27 J. T. Jang, H. Nah, J. H. Lee, S. H. Moon, M. G. Kim and J. Cheon, *Angew. Chem., Int. Ed.*, 2009, **48**, 1234–1238.
- 28 A. G. Kolhatkar, A. C. Jamison, D. Litvinov, R. C. Willson and T. R. Lee, *Int. J. Mol. Sci.*, 2013, **14**, 15977–16009.
- 29 R. E. Rosensweig, *J. Magn. Magn. Mater.*, 2002, **252**, 370–374.
- 30 M. Wegmann and M. Scharr, Synthesis of Magnetic Iron Oxide Nanoparticles, in *Precision Medicine*, ed. H.-P. Deigner and M. Kohl, Academic Press, Furtwangen University, Villingen-Schwenningen, Germany, 2018, ch. 8, pp. 145–181.
- 31 M. R. Ghazanfari, M. Kashefi and M. R. Jaafari, *J. Magn. Magn. Mater.*, 2016, **405**, 88–96.
- 32 A. Tamilvanan, K. Balamurugan, T. Mohanraj, P. Selvakumar and B. Madhankumar, *Mater. Today: Proc.*, 2020, DOI: 10.1016/j.matpr.2020.02.801.
- 33 E. Cheraghpour and M. Pakshir, *J. Environ. Chem. Eng.*, 2021, **9**, 104883.
- 34 Z. Cigeroğlu, G. Küçükyıldız, B. Erim and E. Alp, *J. Mol. Struct.*, 2021, **1224**, 129182.
- 35 S. Ge, X. Shi, K. Sun, C. Li, J. R. Baker, M. M. Banaszak Holl and B. G. Orr, *J. Phys. Chem. C*, 2009, **113**, 13593–13599.
- 36 M. Z. Alam, P. Jamal and M. M. Nadzir, *World J. Microbiol. Biotechnol.*, 2008, **24**, 1177–1185.
- 37 I. Elahi, R. Zahira, K. Mehmood, A. Jamil and N. Amin, *J. Basic Appl. Sci.*, 2012, **6**, 1–5.
- 38 X. Liu, J. Liu, S. Zhang, Z. Nan and Q. Shi, *J. Phys. Chem. C*, 2016, **120**, 1328–1341.
- 39 W. Montha, W. Maneeprakorn, I. M. Tang and W. Pon-On, *RSC Adv.*, 2020, **10**, 40206–40214.
- 40 S. Chakrabarty, A. Dutta and M. Pal, *J. Alloys Compd.*, 2015, **625**, 216–223.
- 41 R. Ludwig, M. Stapf, S. Dutz, R. Müller, U. Teichgräber and I. Hilger, *Nanoscale Res. Lett.*, 2014, **9**, 602.
- 42 P. T. Phong, P. H. Nam, D. H. Manh and I. J. Lee, *J. Magn. Magn. Mater.*, 2017, **433**, 76–83.
- 43 E. Mazarío, J. Sánchez-Marcos, N. Menéndez, M. Cañete, A. Mayoral, S. Rivera-Fernández, J. M. de la Fuente and P. Herrasti, *J. Phys. Chem. C*, 2015, **119**, 6828–6834.
- 44 M. Ma, Y. Wu, J. Zhou, Y. Sun, Y. Zhang and N. Gu, *J. Magn. Magn. Mater.*, 2004, **268**, 33–39.
- 45 C. L. Dennis, A. J. Jackson, J. A. Borchers, R. Ivkov, A. R. Foreman, J. W. Lau, E. Goernitz and C. Gruettner, *J. Appl. Phys.*, 2008, **103**, 07A319.
- 46 M. E. de Sousa, M. B. Fernández van Raap, P. C. Rivas, P. Mendoza Zélis, P. Girardin, G. A. Pasquevich, J. L. Alessandrini, D. Muraca and F. H. Sánchez, *J. Phys. Chem. C*, 2013, **117**, 5436–5445.
- 47 M. E. F. Brollo, J. M. Orozco-Henao, R. López-Ruiz, D. Muraca, C. S. B. Dias, K. R. Pirota and M. Knobel, *J. Magn. Magn. Mater.*, 2016, **397**, 20–27.
- 48 M. Kallumadil, M. Tada, T. Nakagawa, M. Abe, P. Southern and Q. A. Pankhurst, *J. Magn. Magn. Mater.*, 2009, **321**, 1509–1513.
- 49 S. Sharifi, A. Yazdani and K. Rahimi, *Sci. Rep.*, 2020, **10**, 10916.
- 50 V. A. M. Brabers, *J. Phys. Chem. Solids*, 1971, **32**, 2181–2191.
- 51 Y. Miao, Q. Xie, H. Zhang, J. Cai, X. Liu, J. Jiao, S. Hu, A. Ghosal, Y. Yang and H. Fan, *Theranostics*, 2019, **9**, 1764–1776.
- 52 L. Yang, L. Ma, J. Xin, A. Li, C. Sun, R. Wei, B. W. Ren, Z. Chen, H. Lin and J. Gao, *Chem. Mater.*, 2017, **29**, 3038–3047.



- 53 X. Lasheras, M. Insausti, J. M. de la Fuente, I. G. de Muro, I. Castellanos-Rubio, L. Marcano, M. L. Fernández-Gubieda, A. Serrano, R. Martín-Rodríguez, E. Garaio, J. A. García and L. Lezama, *Dalton Trans.*, 2019, **48**, 11480–11491.
- 54 K. Vamvakidis, M. Katsikini, G. Vourlias, M. Angelakeris, E. C. Paloura and C. Dendrinou-Samara, *Dalton Trans.*, 2015, **44**, 5396–5406.
- 55 S. Basu, S. K. M. Hossain, D. Chakravorty and M. Pal, *Curr. Appl. Phys.*, 2011, **11**, 976–980.
- 56 S. Akhnazaroza and V. Kefarov, *Experiment optimization in chemistry and chemical engineering*, Mir Publishers, Moscow and Chicago, 1982, p. 312.
- 57 A. I. Khuri and J. A. Cornell, *Response surfaces: designs and analysis*, CRC Press, New York, 2nd edn, 1987.
- 58 M. S. Tanyildizi, D. Ozer and E. Elibiol, *Process Biochem.*, 2005, **40**, 2291–2296.
- 59 Y. Wu, S. W. Cui, J. Tang and X. Gu, *Food Chem.*, 2007, **105**, 1599–1605.
- 60 M. J. Dalvand, S. S. Mohtasebi and S. Rafiee, *Food Sci. Nutr.*, 2014, **2**, 758–767.
- 61 A. S. Basaleh and S. M. Sheta, *Anal. Bioanal. Chem.*, 2020, **412**, 3153–3165.
- 62 S. M. Sheta, S. M. El-Sheikh, M. M. Abd-Elzaher, M. L. Ghanemc and S. R. Salem, *RSC Adv.*, 2019, **9**, 20463–20471.
- 63 M. Alhaddad and S. M. Sheta, *ACS Omega*, 2020, **5**, 28296–28304.
- 64 D. Chang, M. Lim, J. Goos, R. Qiao, Y. Y. Ng, F. M. Mansfeld, M. Jackson, T. P. Davis and M. Kavallaris, *Front. Pharmacol.*, 2018, **9**, 831.
- 65 P. Leuenberger, S. Ganscha, A. Kahraman, V. Cappelletti, P. J. Boersema, C. Von Mering, M. Claassen and P. Picotti, *Science*, 2017, **355**, eaai7825.
- 66 T. Feng, L. Zhou, Z. Wang, C. Li, Y. Zhang, J. Lin, D. Lu and P. Huang, *Biomaterials*, 2020, **232**, 119709.
- 67 L. Beola, L. Asin, C. Roma-Rodrigues, Y. Fernández-Afonso, R. M. Fratila, D. Serantes, S. Ruta, R. W. Chantrell, A. R. Fernandes, P. V. Baptista, J. M. de la Fuente, V. Grazú and L. Gutiérrez, *ACS Appl. Mater. Interfaces*, 2020, **12**, 43474–43487.
- 68 J. R. Lepock, *Int. J. Hyperthermia*, 2005, **21**, 681–687.
- 69 M. Payne, S. H. Bossmann and M. T. Basel, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2020, **12**, e1638.
- 70 S. Piehler, L. Wucherpfennig, F. L. Tansi, A. Berndt, R. Quaas, U. Teichgraeber and I. Hilger, *Nanomedicine*, 2020, **28**, 102183.
- 71 P. de Andrade Mello, S. Bian, L. Savio, H. Zhang, J. Zhang, W. Junger, M. R. Wink, G. Lenz, A. Buffon, Y. Wu and S. C. Robson, *Oncotarget*, 2017, **8**, 67254–67268.
- 72 S. N. Tabatabaei, M. S. Tabatabaei, H. Girouard and S. Martel, *Int. J. Hyperthermia*, 2016, **32**, 657–665.
- 73 J. Estelrich and M. A. Busquets, Magnetic Nanoparticles as Delivery Systems to Penetrate the Blood-Brain Barrier, in *Nanomedicines for Brain Drug Delivery*, ed. J. O. Morales and P. J. Gaillard, Humana, New York, NY, 2021, vol. 1, p. 157.
- 74 E. M. Scutigliani, Y. Liang, H. Crezee, R. Kanaar and P. M. Krawczyk, *Cancers*, 2021, **13**, 1243.
- 75 T. J. Carter, G. Agliardi, F. Y. Lin, M. Ellis, C. Jones, M. Robson, A. Richard-Londt, P. Southern, M. Lythgoe, M. Zaw Thin, V. Ryzhov, R. T. M. de Rosales, C. Gruettner, M. R. A. Abdollah, R. B. Pedley, Q. A. Pankhurst, T. L. Kalber, S. Brandner, S. Quezada, P. Mulholland, M. Shevtsov and K. Chester, *Small*, 2021, **17**, e2005241.

